Politiparty
Politiparty

118th Congress Health

S. 574: Increasing Prescription Drug Competition Act

Introduced

  1. Introduced (completed)Mar 1, 2023
  2. Passed Senate (not reached)
  3. Passed House (not reached)
  4. To the President (not reached)
  5. Became law (not reached)

Summary

Introduced in Senate, Mar 1, 2023

This bill provides that certifications in generic drug applications of certain patents involved in Risk Evaluation and Mitigation Strategy (REMS) programs have no effect upon the drug's approval. (The Food and Drug Administration sometimes requires a REMS program for certain drugs with safety risks, which may include restrictions on a drug's distribution through elements to ensure safe use (ETASU), such as special requirements for pharmacies that dispense the drug.)

Specifically, certifications in generic drug applications with respect to patents that involve an ETASU for REMS requirements have no effect on the effective date of the drug's approval, notwithstanding any other provisions that allow for a stay of approval pending litigation outcomes (i.e., 30-month stay).

The bill also specifies that in a civil action alleging patent infringement with respect to REMS requirements, the sponsor of the approved brand-name drug may only seek damages from (rather than an injunction against) the generic drug applicant.

Written by the Congressional Research Service, Library of Congress.

Roll calls

0 votes on this bill

No roll call votes have been held on this bill.

Amendments

0 offered

No amendments were offered to this bill.

Cosponsors

1

Bipartisan support.

Who scored on this bill

6 points earned
  1. 1Margaret Hassan D-NH SponsorDrew cross-party cosponsors, introduced2 events+6
See all scorers and every scoring event

Introductions and cosponsorships count toward weekly caps and show no points.

Other bills by Margaret Hassan

History

  1. Mar 1, 2023Introduced in the Senate by Margaret Hassan.
Show the full action history (2 actions)
  1. Mar 1, 2023Introduced in Senate
  2. Mar 1, 2023Read twice and referred to the Committee on Health, Education, Labor, and Pensions.